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To  cope  with  DNA  double  strand  break  (DSB)  genotoxicity,  cells  have  evolved  two  main  repair  path-
ways:  homologous  recombination  which  uses  homologous  DNA  sequences  as  repair  templates,  and
non-homologous  Ku-dependent  end-joining  involving  direct  sealing  of  DSB  ends  by  DNA  ligase  IV (Lig4).
During  the last two decades  a third  player  most  commonly  named  alternative  end-joining  (A-EJ) has
emerged,  which  is  deﬁned  as  any Ku- or Lig4-independent  end-joining  process.  A-EJ  increasingly  appears
as  a  highly  error-prone  bricolage  on  DSBs  and  despite  expanding  exploration,  it still escapes  full charac-NA repair
on-homologous endjoining (NHEJ)




terization.  In the  present  review,  we  discuss  the  mechanism  and regulation  of  A-EJ  as  well as  its biological
relevance  under  physiological  and  pathological  situations,  with  a particular  emphasis  on  chromosomal
instability  and  cancer.  Whether  or not  it is  a genuine  DSB  repair pathway,  A-EJ is  emerging  as  an  impor-
tant  cellular  process  and  understanding  A-EJ will certainly  be  a major  challenge  for  the  coming  years.
© 2014  The  Authors.  Published  by  Elsevier  B.V.  Open access under CC BY-NC-ND license.. Introduction
DNA double strand breaks (DSBs) are the most deleterious
esions inﬂicted on the genome. Discontinuity on both DNA
trands may  prove lethal for the cell if left unrepaired, or lead to
hromosome aberrations and promote tumor development when
isrepaired [1,2].
DSBs  can arise from endogenous sources, mainly correspond-
ng to accidental events like replication fork collapse following
talling or arrest at DNA damage or telomere deprotection [3].
ore specialized mechanisms of DSB formation also exist that rely
n development-associated programmed processes like meiosis
uring gametogenesis [4], or V(D)J recombination [5] and class-
witch recombination (CSR) [6] which facilitate the rearrangements
f antigen receptor genes in lymphogenesis. Aside from these
ndogenous sources, DSBs are also produced by environmental or
edical sources of clastogenic injuries such as ionizing radiation
IR), radiomimetic chemicals or topoisomerase inhibitors [3,7].
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DSB genotoxicity: homologous recombination (HR) which uses
homologous DNA sequences as repair templates [8–10], and non-
homologous end-joining (NHEJ) involving direct sealing of DSB
ends [3,7,11,12].
In  addition to the extensively studied predominant NHEJ path-
way, an alternative end-joining mode (A-EJ) has emerged during
the last two  decades. Here, we  review its mechanism and compare
arguments suggesting that A-EJ relies on a single pathway, on vari-
ous (sub)pathways or on no deﬁned pathway. In addition, we report
mounting evidence that although A-EJ may  have little physiologi-
cal relevance in normal cells due to several concurrent locks, A-EJ
may particularly contribute to cancer through promotion of genetic
instability and chromosomal translocation.
2. Historical overview and deﬁnition of A-EJ
Over the past two decades, the dominant NHEJ pathway has
been thoroughly investigated and its genetic and mechanistic
bases have been largely clariﬁed (for reviews, see [3,7,11–13]).
Brieﬂy, the reaction is initiated by the binding of the Ku com-
plex at each DNA end. Ku is a ring-shaped heterodimer composed
of two subunits (Ku70 and Ku80) able to encircle the free ends.
Once bound, Ku recruits the remaining components of the reac-
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inase (DNA-PKcs). Together these form an active serine/threonine
NA-PK holoenzyme belonging to the phosphatidylinositol 3-
inase-related kinases (PIKKs) family. Besides its essential catalytic
unction, DNA-PK has a major role in maintaining both DNA ends
n close proximity, although recent ﬁndings have indicated a sub-
tantial role of the ligase complex in stabilizing this synapsis [14].
oth the DNA-PK and the ligase complexes are important for DNA
nd processing which is frequently required to make ends ligatable
15]. One of the processing activities is carried out by the structure-
peciﬁc endonuclease Artemis, a DNA-PKcs partner which is also
nvolved in hairpin opening during V(D)J recombination (see below,
ection 4). The ligation complex is composed of DNA ligase IV
Lig4), a homodimer of XRCC4 (X-Ray repair cross-complementing
rotein 4) which is indispensable for Lig4 stability, and the more
ecently identiﬁed Cernunnos homodimer (also known as XRCC4-
ike factor, henceforth referred to as Cer-XLF) whose exact function
emains unclear. The Lig4 complex has no known function aside
rom its essential role in NHEJ, whereas components of the DNA-PK
omplex, especially Ku70/Ku80, have been implicated in multiple
mportant cellular functions such as telomere maintenance [16],
eplication [17], transcription [18] or apoptosis [19].
The  major role of NHEJ in response to IR-induced DSBs or during
he V(D)J recombination is underlined by the cellular radiosen-
itivity (RS) and the severe combined immunodeﬁciency (SCID)
henotype routinely observed when one of the corresponding
enes is mutated, whether in animal models or in human patients
ith hereditary RS-SCID syndromes [20,21].
Although NHEJ plays a critical role in DSB repair, a resid-
al end-joining activity was reported in yeast mutated for Ku80,
u70 or Lig4 [22,23]. The resulting repair products exhibited dele-
ions and were strikingly characterized by a strong dependence on
hort homologous sequences at the junctions [22]. Similar NHEJ-
ndependent end joining activities were also found in mycobacteria
24], Arabidopsis [25], Caenorhabditis elegans [26], Xenopus [27],
hicken [28], as well as in rodent [29–32] and human cells [32–34].
urthermore, when analyzed, the junctions consistently exhibited a
reater use of microhomology (MH), compared to NHEJ. This novel
niversal alternative end-joining mode was susbequently termed
H-mediated end-joining (MMEJ), as opposed to the canonical or
lassical NHEJ, hereinafter called C-NHEJ. Although MMEJ  resem-
les single-strand annealing (SSA), the MMEJ  mechanism differs
y being independent of Rad52 [35,36] and by using signiﬁcantly
horter direct repeats [37]. Although the C-NHEJ-independent end-
oining pathway is biased toward an increased use of MH,  direct
nd joining and MH  usage are not exclusive attributes of C-NHEJ
nd alternative end-joining pathway, respectively [3,38]. More-
ver, apparently direct joints may  yet arise from a MMEJ  process
sing occult MH  through non-templated nucleotide insertion by
 TdT-like polymerase activity of pol [39] or templated inser-
ion by pol [40,41]. Consequently, it seems prefereable to use the
eneric name alternative end-joining (A-EJ) instead of the restric-
ive term MMEJ  and to deﬁne A-EJ as any Ku- or Lig4-independent
nd-joining process [42].
.  Molecular mechanism of A-EJ
.1. A-EJ tools
A-EJ  investigations have beneﬁted from the development of a
arge number of assays that have been set up to study DSB repair
y either NHEJ or HR pathways. Historically, in vitro end-joining
ssays as reviewed in Pastwa and coll. [43] ﬁrst established impor-
ant features of the NHEJ mechanism. The technique is based on
ncubation of linearized plasmid DNA or oligonuclotides bearing
r not modiﬁed ends with cell extracts or puriﬁed proteins. These 17 (2014) 81–97
in  vitro assays brought early insights into the mechanism of A-
EJ [30,34,44–50]. Notably, low Mg2+ concentration were found
to favor DNA-PKcs-dependent end-joining activity [51], whereas
high Mg2+ concentration (10 mM)  facilitated DNA-PK-independent
reaction [34]. In addition, A-EJ preferred high DNA ends/protein
molar ratios [44,52] or was  favored by volume excluders like PEG
[53], possibly indicating a weak intrinsic synapsis activity at DNA
ends.
More recently, in vivo end-joining assays developed to study
NHEJ have also contributed to establish features of A-EJ (Table 1).
They use transient transfection of linearized reporter substrates
followed by plasmid rescue, or cutting of intrachromosomal GFP-
based reporter substrates by the rare endonuclease I-SceI [54].
End-joining is monitored by restoration of reporter gene expres-
sion combined with PCR ampliﬁcation and DNA sequencing of the
junctions. A drawback of transient transfection assays may  be that
signiﬁcant differences in MH usage and/or end-joining efﬁciency
are obtained depending on the transfection method employed
[32,55]. Limitations of intrachromosomal assays concern ﬁrst, the
low frequency of double I-SceI cut at a single locus and second,
underestimation of accurate NHEJ efﬁciency because iterative I-
SceI cutting tends to select inaccurate repair.
Assessing repair of endogenous DSB generated during the two
physiological processes of V(D)J and class-switch recombination
(CSR) that relies on end-joining has also been useful to character-
ize A-EJ under conditions of C-NHEJ deﬁciency (Table 1). Although
repair is measured on endogenous substrates, conclusions from
these assays may  not be entirely transposable to repair of any DSB.
V(D)J recombination breaks are preferentially constrained to C-
NHEJ and repetitive context sequence of CSR breaks favors MH
usage. Finally, we  have used a cellular fractionation protocol to
study A-EJ in native chromatin. After treatment with a strong DSB
inducer followed by western-blotting or immunostaining, recruit-
ment of A-EJ proteins to damaged chromatin can be studied in cells
engineered for Ku depletion [56].
3.2. A-EJ players
Based  on the C-NHEJ mechanism, the A-EJ reaction likely relies
on at least three main steps (Fig. 1). First, the two  DNA ends
must be recognized and held together. Second, although some-
times dispensable, most of DNA ends require processing to make
them ligatable. Several enzymatic activities may  participate in this
step such as various types of nucleases, dRP lysases, kinases, phos-
phatases, helicases and polymerases. Third, the ﬁnal step requires
a DNA ligase and according to the proposed deﬁnition of A-EJ, this
step in mammals should rely on DNA ligase III (Lig3) and/or DNA
ligase I (Lig1).
In  the next sections, we review the protein components poten-
tially involved in the recognition/synapsis, processing and ligation
steps of A-EJ.
3.2.1.  End recognition and tethering of DSB ends
Several reports have established a role for poly(ADP-ribose)
polymerase 1 (PARP1) in early steps of A-EJ. PARP1 is a sensor of
DNA damage that binds to single strand breaks (SSBs) and DSBs,
gets activated and catalyzes the poly(ADP-ribosyl)ation of proteins
at DNA damage sites (reviewed in [57], [58]). The well documented
role of PARP1 in SSB repair is to recruit factors including the ligation
complex XRCC1/Lig3 to promote repair via DNA end processing and
ligation [59]. PARP1 also participates in the initial accumulation of
the MRE11/RAD50/NBS1 (MRN) complex to DSBs [60].Concomitantly to the ﬁnding that PARP inhibitors increase the
sensitivity of DNA-PK-deﬁcient cells to radiomimetic-induced DSBs
[45], biochemical experiments [45,48,49] and plasmid assays in Ku-
deﬁcient cells [61] substantiated the involvement of PARP1 in a non
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Table  1
In  vivo assays to explore A-EJ.
DSB location Repair event Origin of DSBs Signiﬁcant References
Transfected vector DSBR Restriction enzyme [22,31,32,61,78,109,288]
V(D)J  RAG [32,132,139,289,290]
Integrated  cassette DSBR  I-SceI [35,72,73,83,110,111,118,180,246,291–297]
V(D)J  RAG [70,137,138,140,159,244,257,298,299]
CSR  I-SceI [185]
Translocation I-SceI, RAG ± I-SceI, AID,
Cre
[81,180,243–245,264,300–303]
Genomic  DNA V(D)J RAG [133,134,136,261,304]
CSR  AID [62,71,82,95,100,116,118,149–152,154,160,161,163,168,169,171,
174,180,182,184,185,264,305–307]



























rRAG,  AID, spontan
-NHEJ mode of DSB repair, possibly through both tethering of DSB
nds and protein scaffolding activities [45].
In the context of AID-induced DNA breaks generated during CSR,
witch junctions in PARP1-deﬁcient B cells are biased towards an
bsence of MH,  indicating that PARP1 facilitates repair through A-
J [62]. The fusion of deprotected telomeres in Ku-deﬁcient cells
s signiﬁcantly reduced upon repression of PARP1 with an shRNA
r treatment with a PARP inhibitor [63]. In Ku-deﬁcient CHO cells,
iRNA-mediated PARP1 depletion result in a severe defect in end-
oining of chromosomal I-SceI DSB indicating that PARP1 may
romote chromosomal A-EJ speciﬁcally in the absence of Ku [63]. A
irect competition between PARP and Ku for binding to DNA ends
61] together with the ﬁnding that Ku inhibits PARP1 recruitment,
oly(ADP-ribose) synthesis and generation of single-stranded DNA
56] suggest that suppression of A-EJ is mainly attributed to the
resence of Ku at DNA ends (see below, section 4). Recently, a role
f PARP in plant A-EJ was also conﬁrmed as PARP mutants dis-
layed less A-EJ products analyzed in an in vitro end-joining assay
n Arabidopsis [64].In  addition to its possible role in A-EJ through tethering of DNA
nds as supported by structural studies [65], PARP1 may  also serve
n this process as a platform for directly or indirectly recruiting
actors such as XRCC1, Lig3, PNK [33,45,48] and MRN  [56]. The latter
ig. 1. A “catch-all” model for A-EJ. The three main steps of the reaction are depicted as we
-EJ factors. See the text for details (section 3.2). On both sides are indicated additional DN
epair;  NER, nucleotide excision repair; HR, homologous recombination; SSA, single-stran[62,95,100,152,154,162,163,171,240,261,269,302,309,310]
may also contribute to tethering of DSB ends in A-EJ through its
bridging function [66].
3.2.2.  DSB processing
3.2.2.1.  End resection. A current model is that, when necessary, A-
EJ uses DNA resection to reveal single-stranded MHs that have
to anneal before joining, therefore requiring nucleolytic DNA end
processing [67]. As established for HR, the process of end resection
comprises two  steps: ﬁrst, relative short stretches of ssDNA are
produced by the combined action of MRN  and C-terminal binding
protein interacting protein (CtIP); then the EXO1 exonuclease or
the Bloom (BLM) (Sgs1 in S. cerevisiae)/Dna2 endonuclease complex
perform a more extensive resection (for review, [68]).
In  S. cerevisiae, through the use of HO endonuclease to create
DSBs, it was  shown that Mre11 and Rad50 are required for MMEJ
[36,69].
In mammals, by using a mutated RAG2 protein that permits A-
EJ-mediated repair of V(D)J coding-joint formation, Roth’s group
revealed a role for NBS1 in V(D)J coding-joint formation in the
absence of Artemis or DNA-PKcs [70]. In both human and murine
cell lines the role of MRE11 in NHEJ has been assessed by studying
the repair of I-SceI endonuclease-induced DSBs [71–73]. Reduc-
tion of MRE11 protein level or chemical inhibition of MRE11
ll as the corresponding protein factors involved. Brackets signal minor or equivocal
A transaction/repair pathways to which also belong these factors. BER, base excision
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ecreased chromosomal end-joining in wild-type as well as XRCC4-
eﬁcient backgrounds, potentially implicating MRE11 in both
-NHEJ and A-EJ [72,73]. In this context, the MRN  complex and the
RN-interacting CtIP probably work together, since depletion of
BS1 [74], RAD50 [72] or CtIP [72,73] in wild-type or XRCC4-
efective cells also leads to a similar decrease in overall end joining.
Another study provided new insights into the mechanism of
RE11 during end-joining in human embryonic kidney cells con-
aining a chromosomally integrated NHEJ substrate [75]. Silencing
f MRE11 with siRNA leads to a signiﬁcant reduction in MH-
ediated deletional end joining compared with siRNA control
ells. The frequency of A-EJ was signiﬁcantly suppressed by siRNA-
ediated MRE11 silencing whereas the frequency of C-NHEJ was
ot changed [75].
CtIP  is required for DSB resection and participates, in coop-
ration with the MRN  complex, in several DNA repair pathways
ncluding HR and A-EJ [35,76–78]. Short-interfering-RNA-mediated
nockdown of CtIP in HEK293 cells [35] and knockout of CtIP in
T40 cells [78] result in a signiﬁcant reduction in A-EJ. These data
stablish a role for CtIP in A-EJ thereby explaining the defects in
verall DSB repair observed in CtIP mutants cells during G1 in
esponse to X-ray damage [78]. Moreover, in the absence of H2AX,
tIP promotes hairpin opening and DNA end resection of RAG-
ediated DSBs in G1-phase lymphocytes [79,80]. CtIP has also been
mplicated in the A-EJ-mediated formation of translocations orig-
nating from I-SceI-induced DSB in mouse embryonic stem cells
81]. Furthermore, in the physiological context of CSR, knockdown
f CtIP expression in the mouse B cell line CH12F3 results in a
eduction of CSR along with a signiﬁcant decrease of the aver-
ge MH  length at S-S junctions, thereby providing evidence for
he requirement of CtIP for MH-directed A-EJ during CSR; addi-
ional data in this study demonstrated that CtIP is also involved in
H end-joining in Ku70-deﬁcient cells [82]. Truong and coll. used
n MMEJ  and HR competition repair substrate in human cells and
emonstrated that MRN  and CtIP are required for the initial short-
ange end resection to promote MMEJ  and that BLM and EXO1 are
eeded for extended end resection and HR [83]. Additionally, CtIP
lso supports resection associated with A-EJ dependent telomere
usions in various models [63,84].
.2.2.2. Polymerase, ﬂap endonuclease, helicase and polynucleotide
inase. In yeast, the translesion DNA polymerases Pol (Rad30 or
olH) and Pol (Rev3/Rev7), Pol4 (most homologous to Pol and
ol of the X family in mammals) and also the processive Pol,
hrough its accessory protein Pol32, have been proposed to partici-
ate in A-EJ [69,85]. Lee and Lee, using in vivo end-joining assays to
epair HO-induced DSBs, proposed that Pol, Pol (Rad30) and Pol
Rev3) may  contribute to MH-mediated end joining by extending
ynthesis beyond initial gap ﬁll-in synthesis by Pol4 [69]. Using a
epair assay that allows discrimination between C-NHEJ and A-EJ
vents based on the sensitivity to hygromycin, more recent studies
n yeast show that deletion of Pol32 also severely reduces MH-
ediated repair [86]. The role of Pol32 in MH-mediated repair is
nlikely to recruit translesion polymerases because deletion of Pol
Rev3) and/or Pol (Rad30) does not impact MH-mediated repair,
ut rather stabilizes the annealing intermediate between single-
trand DNA to allow Pol to extend the annealed homologous
equences and complete the repair process [86].
The mammalian ortholog of S. cerevisiae Pol4 is Pol, a X fam-
ly member of repair polymerases. Its structural and biochemical
eatures make mammalian Pol a likely candidate for the synthesis
tep in A-EJ, which involves unstable primer-template junctions
esulting from annealing of 3′-ssDNA overhangs at MH  regions.
ol preferentially ﬁlls gaps with ends bearing partial complemen-
ary overhangs [39]. Indeed, in a minimal in vitro system, Pol and 17 (2014) 81–97
Lig1  but not Pol	 are able to carry out MH-mediated end joining of
broken DNA ends with terminal MH  [87].
In D. melanogaster which lacks PolX members, Pol (PolQ) partic-
ipates in alternative end-joining in response to P element-induced
breaks or ISce-I mediated DSBs that operate independently of both
Rad51-mediated HR and Lig4-dependent C-NHEJ. Genetic analysis
provide support for distinct roles of N-terminal helicase-like and
C-terminal polymerase domains in a model where both activities
cooperate to generate single-stranded MH  sequences used in A-
EJ [40]. The role of Pol in A-EJ in other organisms remains to be
explored.
Yeast Rad1 and Rad10 proteins form a stable endonuclease com-
plex that is required for several DNA repair pathways including
nucleotide excision repair (NER) end HR. Genetic observations sug-
gested that Rad1 and Rad10 may  be needed for MMEJ  by removing
the 3′-ﬂap DNA that forms upon annealing of MH. Indeed, dele-
tion of both yeast Rad1 and Ku70 leads to a synergistic reduction in
survival after induction of DSB by endonuclease HO [36]. These ﬁnd-
ings were supported by Villarreal and coll. showing that deletion
of Rad1 reduced MH-mediated repair frequency [86]. Rad1-Rad10
activity in DSB repair are conserved in mammals, since the mam-
malian ortholog ERCC1-XPF also contributes to DSB repair in a
Ku80-independent manner characteristic of A-EJ [88].
Despite  its 5′ endo/exonuclease activity, Flap endonuclease-1
(FEN1) protein has also been proposed as a candidate in A-EJ. FEN-
1 was detected in a partially puriﬁed fraction from Xenopus egg
extracts devoid of Ku70/80 and DNA-PK and that contained an
error-prone NHEJ activity that created deletion at patches of MH
[27]. In a cell-free DNA end-joining assay, FEN1 was also found
to be required for MH-mediated DSB repair in mammalian cells
[44]. It was proposed that FEN1 endonuclease activity rather than
its 5′ exonuclease activity could be involved in A-EJ; alternatively
FEN1 may  play other roles in A-EJ through its interaction with poly-
merases [89].
Addition of phosphate to the 5′-terminal end represents a
limiting step for the repair of non-ligatable DNA ends. The major
human 5′-DNA kinase activity relies on polynucleotide kinase
(PNK) and hPNK directly interacts with the XRCC1 protein [90].
Given that the XRCC1/Lig3 complex is implicated in the PARP1-
dependent A-EJ pathway [45], hPNK is suitable to play a role in
A-EJ. In support of this idea, PNK is co-recruited to DNA ends with
PARP1 and XRCC1/Lig3 and the ligation of 5′-OH terminal breaks is
compromised in hPNK-depleted extracts [48].
3.2.3. DSB ligation
Lig4  associated with XRCC4 is dedicated to the repair of DSBs
by the C-NHEJ pathway and there are no known function for this
ligase outside this process [3]. Thus, much interest has focused on
the possible role of the two  other mammalian ligases (Lig1 and Lig3)
for the joining of DNA ends in A-EJ.
Results from plasmid joining assays and biochemical experi-
ments implicated Lig3 in A-EJ [33,45,47,91]. Structural evidence
such as the presence of a zinc-ﬁnger domain which facilitates
intermolecular ligation are compatible with its possible involve-
ment in A-EJ [92]. Interestingly, ligation of incompatible ends by
Lig3/XRCC1 is stimulated by MRN  [33]. Lig3 has both nuclear and
mitochondrial isoforms, the former associated with XRCC1 [93].
The recent development of mouse cell lines that are speciﬁcally
deﬁcient for the nuclear form of Lig3 has permitted investiga-
tion of its role in chromosomal translocation formation and A-EJ
[94]. Nuclear Lig3-deﬁcient cells show a reduced translocation
frequency between two  zinc-ﬁnger endonuclease-induced chro-
mosomal DSBs, suggesting that Lig3-dependent A-EJ contributes
to translocation events despite the presence of all C-NHEJ factors
[94]. In contrast, Lig3 depletion through shRNA expression in wild-
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ot impair CSR assayed by IgA switching or formation of IgH/c-
yc translocations [95]. However, these results may  be explained
y a low residual Lig3 level contributing to the A-EJ observed in
ig4-deﬁcient cells and do not deﬁnitely rule out a dominant role
f Lig3 in A-EJ [96].
XRCC1  is a scaffolding protein that stabilizes Lig3 so that Lig3
rotein levels are drastically reduced in XRCC1-deﬁcient cells [97].
ased on biochemical experiments, XRCC1 has been described
s a mammalian A-EJ factor [33,45]. Another line of evidence
mplicating XRCC1 in A-EJ comes from its involvement in Ku-
ndependent repair in Arabidopsis thaliana [98]. However, since
lants are lacking a Lig3 homolog, Arabidopsis may  function by
ecruiting other factors to carry out DSB repair in the absence of
-NHEJ.
Conditional XRCC1 inactivation in mature primary wild-type
r XRCC4-deﬁcient B cells does not impair A-EJ-mediated switch
unctions (S-S
1 and S-S junctions), alter the frequency of
gH/c-myc translocations nor compromise the repair of I-SceI-
nduced chromosomal DSB [95]. Similarly, genetic ablation of
RCC1 in Lig4 deﬁcient CH12F3 B cells does not reduce their abil-
ty to undergo CSR nor did it affect MH at switch junctions [99].
ogether these results indicate that XRCC1 may  not be required
or A-EJ in the CSR context, although conﬂicting results have been
eported [100]. In addition, Lig3 interaction with XRCC1 appears
ispensable for A-EJ-mediated translocation in mouse cells [94]
nd XRCC1 mutation in a CHO cell line does not abrogate MH  use
easured using an extrachromosomal assay, also suggesting that
RCC1 is not required for A-EJ [32]. However, a contribution of
RCC1 to A-EJ of IR-induced breaks in G2 was recently reported in
amster cells [101]. Thus, the requirement for XRCC1 in A-EJ may
ary in different models depending on whether DNA Lig3 activity
s limiting or not in each corresponding situation.
Besides Lig3, Lig1 has also been implicated in A-EJ. Indeed,
iRNA-mediated downregulation of Lig1 in human HTD114 cells
eads to a reduction of MH-mediated end joining of linearized plas-
ids in cell-free extracts [91]. However, when DSBs are introduced
t two loci by expressing zinc ﬁnger nucleases, Lig1 depletion in
ild-type mouse cells do not have any effect on translocation
requency whereas Lig1 depletion in nuclear Lig3-deﬁcient cells
early abolishes translocations [94]. The involvement of Lig1 was
urther demonstrated in Lig3/Lig4 double mutant DT40 cells in
hich Lig1 contributes to the remaining alternative end-joining
ctivity observed in these cells [102]. This implies that Lig1 may
ct as a back-up ligase for Lig3 in A-EJ.
These results may  reﬂect the existence of at least two A-
J pathways with Lig1 and Lig3 operating hierarchically, one
ig3-dependent pathway biased toward MH use, and a second Lig1-
ependent pathway independent of MH [94].
. Regulation of A-EJ
What  makes A-EJ a marginal repair route for DSB under normal
onditions?
The ﬁrst likely reason is that the major C-NHEJ pathway relies on
 champion DNA end binding factor, namely Ku. Ku is not only very
bundant but also exhibits a very high afﬁnity for DNA ends [3,103].
evertheless, PARP1 also binds to and is activated by DSBs in vitro
104,105]. Indeed, biochemical experiments provide evidence for a
ompetition between puriﬁed Ku complex and PARP1 at DNA ends
61]. In cells however, the frequently associated SSBs after com-
on clastogenic treatment (∼20 fold ratio of SSBs to DSBs afterR) most probably divert PARP1 from DSBs [61]. PARP1 binding to,
nd activation by DSBs may  further be down-regulated by DNA-PK
ctivity [56,106]. However, it is conceivable that a marginal fraction
f breaks that initially engaged in resection may  escape C-NHEJ by 17 (2014) 81–97 85
preventing Ku loading and enter the A-EJ route [62,83,107] which
may also support translocations in wild-type cells [81].
As  compared to other C-NHEJ proteins, several ﬁndings support
a major role of Ku for preventing access at DSBs to non C-NHEJ fac-
tors. For example in yeast, loss of either orthologs of Lig4 or XRCC4
has a milder effect on MRE11-dependent resection at DSBs than
loss of Ku [108]. In plasmid-rejoining assays in human cells, Ku80
genetic ablation still allows a wild-type level of repair events. Inac-
tivation of DNA-PKcs, Cer-XLF or Lig4, however, strongly inhibits
repair, although this can be rescued by reducing the amount of
Ku in these cells [109]. Similarly, joining efﬁciency of an intra-
chromosomal substrate is close to normal in Ku-deﬁcient hamster
cells but strongly reduced in XRCC4-defective cells [110]; in mouse
embryonic ﬁbroblats (MEFs), plasmid end-joining is decreased by
XRCC4 defect but not by lack of Ku [111]. A PARP inhibitor com-
promised DSB repair in Ku-defective cells to a greater extent than
in cells defective in other C-NHEJ factors [45,61,112]. In addition,
we and others found that the recovery of A-EJ factors in damaged
chromatin was stronger in the absence of Ku than in the absence of
other C-NHEJ proteins [56,112].
A second reason for the marginal contribution of A-EJ to normal
DSB repair is that C-NHEJ relies on a very efﬁcient and ﬂexi-
ble process, perfectly equipped to handle most of DSB classes
[3]. This likely reﬂects the evolution of numerous protein/DNA
and protein/protein interactions that optimize tethering, protec-
ting, processing and end-joining activities necessary for repair of
DSBs [3,13,113]. In addition, several results demonstrate functional
cooperation within the C-NHEJ supra-molecular active complex
so that each protein optimizes the activity of the other partners:
for example, ligation proteins also optimize tethering [14] and
processing of DNA ends [15,114]. Thus, A-EJ which rather appears as
a  composite process depending on the somehow fortuitous assem-
bly of disparate components (see Fig. 1 and last section 6) cannot
compete with the evolutionary selected C-NHEJ pathway. Accord-
ingly, Iliakis’s group has reported that while most IR-induced
breaks are repaired with a fast kinetics by the C-NHEJ pathway (typ-
ical half life <30 min), the DSB repair that still occurred in C-NHEJ
mutants that was not dependent on HR, proceeded much slowly
([115] and references therein).
The  tight regulation of DSB resection acts as a key determinant in
committing the repair of a DSB to either C-NHEJ or homology-based
pathways including A-EJ (Fig. 2), which may  also contribute to C-
NHEJ predominance. Indeed, an admitted although optional trait
of A-EJ is that it shares with HR a common initial resection mecha-
nism promoted by the MRE11 nuclease and CtIP (see above, section
3.2.2.1). Furthermore 53BP1 is a major inhibitor of resection at DNA
ends, operating through recruitment of at least RIF1 to its own
ATM-dependent phosphosites [116–120]. The absence of 53BP1
increases end resection and channels repair to A-EJ in CSR [121].
Similarly, in U2OS cells transfected with linearized plasmids, RIF1
depletion leads to an increase in resection-based repair pathways
including A-EJ [118]. Most probably through the same route, 
H2AX
or its binder MDC1 prevent CtIP-dependent resection and A-EJ at
V(D)J DSBs in G1 murine lymphocytes [118]. Consequently, A-EJ
shares with HR the cell-cycle regulation of resection, i.e. repres-
sion in G1 and expression in S/G2 phases through CDK  activity
(reviewed in [68] for HR). Indeed, the DSB repair defect in BRCA2-
deﬁcient cells is rescued by A-EJ under certain conditions [101]. A-EJ
of IR-induced breaks or transfected plasmid in MEFs deﬁcient for C-
NHEJ and/or HR is efﬁcient in G1, but further increased in G2  [122].
More recently, using a GFP-reporter A-EJ repair substrate, Truong
and coll. showed that A-EJ requires cyclin-dependent activities and
increases signiﬁcantly as cells enter S-phase [83]. Together these
studies suggest that A-EJ is active in all the phases of the cell cycle
but in contrast to C-NHEJ, it increases as cells enter S-phase, con-
comitantly with CDK activity (Fig. 2). In addition, growth state also
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Fig. 2. Interplay between DSB repair pathways—Role of cell cycle and resection. C-
NHEJ dominates both A-EJ and HR for the repair of DSBs, primarily by Ku competing
(with  PARP1) for the access to the breaks. Regulation of DNA end resection in a cell
cycle-dependent manner is also critical for the repair pathway choice. In this respect,
the ATM-dependent DDR pathway (MRN-ATM-H2AX) has no decision-making role
per se but rather facilitates DSB repair by either C-NHEJ or HR, in G1 or S/G2 phases
of the cell cycle, respectively. More speciﬁcally, activation of ATM leads to phos-
phorylation of 53BP1 and the subsequent formation of 53BP1/RIF1 complexes that
accumulate at the breaks. In G1, 53BP1/RIF1 opposes BRCA1 and CtIP, thus limiting
end resection and supporting C-NHEJ, particularly for complex DSBs and/or for DSBs
arising in the heterochromatin. In S and G2, although C-NHEJ remains the predomi-
nent pathway, CDK1 phosphorylates CtIP enabling its association with BRCA1. The































mromoting end resection-dependent repair processes. The extension of resection
arried  out by EXO1 further bolsters up HR which dominates A-EJ. See the text for
urther details.
nﬂuences A-EJ since IR-induced DSB repair is markedly reduced in
lateau-phase cultures of Lig4-null [123] or Ku-null [124] but not
ild-type MEFs. In addition serum deprivation impacts on survival
f C-NHEJ defective but not wild-type MEFs [125].
Finally, DSBs origin, complexity or context may  inﬂuence
he repair pathway choice. Concerning the origin of the DSB,
echanisms dedicated to avoid A-EJ operate at specialized breaks,
ike the ones occurring during V(D)J recombination. This pro-
ess corresponds to a genetic rearrangement between exons
ncoding the amino-terminal variable regions of B- and T-cell
eceptors during lympocyte development [5,38,126]. It is initi-
ted by RAG1/2 heterodimeric nuclease which introduces DSBs
t cognate recombination signal sequences ﬂanking the gene
egments to recombine [5]. RAG-induced DSBs are speciﬁcally
hanneled to C-NHEJ as a result of several RAG properties. First,
AG expression is restrained to the G1 phase of the cell cycle
127], precluding resection-based V(D)J DSB repair mechanisms
n normal conditions. Also, one side of each V(D)J DSB harbors a
airpin which requires processing mostly by Artemis, the C-NHEJ
tructure speciﬁc nuclease [128,129]. Finally, the RAG complex
ransmits the breaks speciﬁcally to the C-NHEJ machinery, so that
n the absence of C-NHEJ core components, virtually no B or T cells
an develop. This results in Severe Combined Immuno-Deﬁciency
henotype as described in mice deﬁcient for XRCC4 [130–132],
ig4 [133], Ku80 [132,134–136], or Ku70 [137,138]. RAG-mediated
ias for C-NHEJ is further substantiated by the observation that
he repair of RAG-independent breaks generated by I-SceI-RAG
usion proteins is restricted to C-NHEJ [139]. Furthermore, RAG
utants have been described that enabled A-EJ to access and rejoin 17 (2014) 81–97
RAG-dependent  DSBs, even in C-NHEJ proﬁcient cells albeit to
a lesser extent [140–142], resulting in increased translocation
frequency and high incidence of lymphomas in a p53-null murine
genetic background [143]. A-EJ restriction is dependent on a
particular RAG2 subdomain [144]. Consequently, under normal
conditions, the role of A-EJ in the V(D)J recombination is reduced to
the smallest share since it is highly unlikely that the A-EJ machinery
has a chance to encounter and deal with RAG-induced DSBs.
Increasing  complexity of DNA ends also may  affect the rate
of the reaction, the requirement for processing events including
resection, and thereby inﬂuence the relative contribution of C-
NHEJ, HR and A-EJ. Early in vitro experiments documented the
inﬂuence of DNA end compatibility on both the efﬁciency and accu-
racy of C-NHEJ and A-EJ [30,31], as well as the position of MH
relative to the ends on the propensity to perform MMEJ [31,44,145].
The presence of repetitive sequences in the vicinity of the break
may favor A-EJ over C-NHEJ and HR. This notion is consistent with
the necessity of tightly silencing A-EJ at the telomere, and with
the ability of A-EJ to signiﬁcantly rescue C-NHEJ deﬁciency during
the CSR process in which DSBs are formed in regions containing
repeated motifs (see the following sections 5-1 and 5-2).
In  summary, although A-EJ is largely dominated by both the C-
NHEJ and HR pathways, it can serve as a backup pathway not only
for C-NHEJ, particularly in G1 when HR is inoperative, but also in
G2 for HR when extended resection precludes C-NHEJ activity.
5.  Physiological relevance of A-EJ
5.1. Class-switch recombination (CSR)
CSR is a cellular process occurring in peripheral IgM-expressing
B lymphocytes (mature B cells) in response to antigen-dependent
stimulation. It is an intrachromosomal deletional recombination
requiring two initial DSBs (like V(D)J recombination). CSR is respon-
sible for exchanging the immunoglobulin isotype from IgM to IgG,
IgA or IgE by recombining the corresponding Ig constant chain
exons, thus generating antibodies with different effector functions
[6,38,146]. In contrast to DSBs that arise during the V(D)J recom-
bination, CSR-dependent DSBs are not produced by a site-speciﬁc
recombinase but are generated by a complex mechanism initiated
by the Activation-Induced Cytidine Deaminase (AID) [6,146]. AID
operates at both the donor S switch region (upstream the C
constant region) and one acceptor S region adjoining the heavy
chain constant region that is to undergo recombination. S, S
and S regions are composed of GC-rich pentamer tandem repeats,
whereas S
 regions mainly contain larger tandem repeats [147].
Transcription at S regions facilitates AID-dependent deamination of
deoxycytidines in single-stranded DNA, resulting in deoxyuridines
that are subsequently processed by the BER pathway via the Uracil
N-glycosylase (UNG), giving rise to SSBs [6]. Proximal SSBs on oppo-
site strands, like those arising at pentamers containing a GC motif,
then result in DSBs [148].
DSBs  generation during CSR is not believed to be particularly
constrained to C-NHEJ as compared to the V(D)J recombination
(see above, section 4). Indeed, when V(D)J abrogation in C-NHEJ
deﬁcient mice is artiﬁcially circumvented to allow production of
mature B cells, it appears that, although affected, substantial CSR
can occur in murine lymphocytes deﬁcient for XRCC4 or Lig4
[149–152], DNA-PKcs [153–157], Artemis [156,158], Cer-XLF [159],
and also Ku70 or Ku80 [149]. Consistent with a role for A-EJ in oper-
ating during CSR in the absence of C-NHEJ, the frequency and length
of MH at S-S junctions are enhanced [149,151,152,159]. Similar
results are found in S-S junctions in cells from patients deﬁcient
for Lig4 [160], Artemis [158,161] and Cer-XLF [162]. However, S-
S
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o use MH  depends on the degree of homology between S regions.
f note, Lig4 mutations in patients are hypomorphic [160] and, in
he case of Artemis, S-S
 junctions could not be recovered from
Artemis-null” patients and were only found in a patient carrying a
ypomorphic mutation [161]. Hence the extent of homology at the
-S junction may  inﬂuence the capacity of A-EJ to compete with
esidual C-NHEJ for the rejoining of S regions, allowing only Lig4
r Artemis hypomorphic mutants to reseal some poorly homolog
-S
 pairs.
Besides the less frequent S-S junctions in C-NHEJ deﬁcient B
ells, non-productive recombination events may  arise during CSR
ollowing the rejoining of two AID-dependent DSBs within a given S
egion, which results in internal switch deletion (ISD). Compared to
SDs occurring in wild-type B cells, ISDs in C-NHEJ deﬁcient B cells
re recovered at a much higher frequency and the junctions exhibit
 more pronounced MH usage [163]. These observations indicate
hat A-EJ is more prone to catalyze short-range intrachromosomal
eactions than standard long-range reactions (as well as interchro-
osomal translocations, see below, section 5-3). This phenotype
ikely accounts for the increased opportunity for A-EJ to ﬁnd and use
icro-homologous sequences within a given S region as compared
o between different S regions.
Apart from the dominant activity of C-NHEJ over A-EJ, the
ethering of distal S regions necessary for functional CSR may
lso inﬂuence the DSB repair pathway choice. Indeed, in contrast
o the moderate role of the ATM-dependent DSB response path-
ay in V(D)J recombination, efﬁcient CSR was  found to require
RN [71,74,164–166], ATM [165,167–169], H2AX [170–174],
DC1 [171,175], RNF8 [176–178], RNF168 [177,179], 53BP1
121,180–183] and RIF1 [116–120]. This probably reﬂects the
ecessity to stabilize the synapsis between two  distant DSBs in
he absence of a RAG-like complex. Inactivation of any of these
SB response factors results in CSR impairment and genomic insta-
ility, albeit to varying degrees. 53BP1 deletion apparently leads
o the most severe defect, by preferentially affecting long-range
-S recombination whereas non productive ISDs are enhanced
180,182]. In addition to stabilizing the synapsis, DNA damage
esponse factors also promote efﬁcient CSR by protecting DNA
nds from degradation in a distance-independent manner as shown
or 53BP1, thus further favoring C-NHEJ [121]. In agreement, in
3BP1, ATM or H2AX deﬁcient mouse B cells, S-S junctions exhibit
ncreased deletion and MH  usage, indicative of end processing by
-EJ [121,167,180]. However, in the case of poorly homologous
-S
1 junctions, no MH  change [169] and increased MH have
een reported [167] in the absence of ATM, although identical
ouse strains were used in both experiments. Among hypothe-
es to explain this discrepancy are the cell source and, more likely,
he stimulation protocol. In this regard, CD40L + IL4 [167] would
e more suitable than LPS + IL4 [169] for studying MH  variations
t S-S
1 junctions. Accordingly, when MH usage was analyzed
pon XRCC4 conditional deletion in mouse B cells, no change was
bserved when switching to IgG1 with LPS + IL4 [151], whereas the
verage junctional MH was increased by three fold when using
D40L + IL4 [152]. This indicates that both the S-S combinations
nd the stimulation protocol chosen are to be considered when
nterpreting MH  usage and the supposedly related A-EJ activity in
SR. CSR junctions were also analyzed in human patients deﬁcient
or various components of the DNA damage response. In Ataxia
elangiectasia (AT) patients, MHs  were notably increased at S-S
unctions, even over 10 bp and, less markedly, at S-S
 junctions
165,184]. In NBS1 (Nijmegen breakage syndrome, NBS) and MRE11
AT like disorder, ATLD) deﬁcient patients, milder CSR defects are
eported with still increased MH usage and signiﬁcantly more S-
 junctions ﬂanked by long imperfect repeats [164,165]. Worthy
f note is the pattern of MH  usage found in ATR deﬁcient patients
Seckel syndrome) featuring increased 4–6 bp MH  but normal MH 17 (2014) 81–97 87
usage for longer stretches, in contrast to ATM [184], probably
accounting for speciﬁc role of ATM and ATR in regulating limited
and extended resection, respectively.
Paradoxically, ATM inhibition reduces the CSR defect in 53BP1
deﬁcient mouse cells by decreasing resection [121]. This suggests
that, as in V(D)J recombination, ATM assumes antagonistic roles
in stabilizing the synapsis and favoring end resection, thus pro-
moting C-NHEJ and A-EJ, respectively. In this respect, the MRN
complex also appears to be a multifunctional factor, involved both
in synapsis stabilization through its bridging function, and in the
regulation of end resection [66]. In mouse B cells, MRE11 dele-
tion profoundly impaired CSR (more than ATM deletion) and led
to slightly less MH  at S-S junctions. In contrast MRE11 nucle-
ase activity was  partly dispensable for CSR and its inactivation
resulted in unchanged MH  usage at S-S junctions, [71]. In this
context and constrasting with MRN, CtIP seems to only promote
resection during CSR. Its knockdown results in less MH usage
both in Ku70-deﬁcient and in wild-type murine B cells [82]. This
indicates that C-NHEJ can accommodate to some extent to CtIP-
dependent resected DNA ends and/or that A-EJ may  contribute
to normal CSR. Recently, CtIP or EXO1 inactivation was shown to
only partially abrogate resection and rescue CSR defect in 53BP1-
null mouse B lymphocytes, supporting their role in A-EJ, but also
revealing their functional redundancy or the existence of additional
resection mechanism operating during A-EJ [185].
As  for a role of A-EJ in normal CSR (i.e. in the presence of C-NHEJ),
some S junctions in C-NHEJ proﬁcient human [160] and murine B
cells frequently use MHs  above four nucleotides [149,152], con-
sistent with A-EJ repair products. Furthermore, ISDs in C-NHEJ
proﬁcient cells [160] also exhibit frequent use of MH  and were pro-
posed as a readout of A-EJ activity [149,152]. However, repetitive
sequences in S regions constitute a breeding ground for any MH-
mediated end-joining process, making delusive any interpretation
about the respective contribution of A-EJ or C-NHEJ on the sole
basis of MH  usage. Investigating the role of nuclear Lig3 in both S-
S junctions and ISDs should therefore prove highly informative in
evaluating the actual role of A-EJ in CSR.
5.2. A-EJ and telomeres
A  major challenge for eukaryotic cells is to prevent the ends of
their linear chromosomes from recognition as DSBs by the DNA
repair and signaling machinery. In most eukaryotes, specialized
nucleoprotein complexes, called telomeres, protect chromosome
ends.
In mammals, telomeric DNA consists of a double-stranded
region, based on the repetition of the hexameric TTAGGG sequence,
extended by a 3′ protruding single-stranded G-rich sequence, the
G-tail or telomeric overhang. Telomeric DNA is bound by a speciﬁc
telomeric complex called shelterin that is composed of TRF1, TRF2,
RAP1, TIN2, TPP1 and POT1 proteins. Whereas TRF1 and TRF2/RAP1
proteins are associated with double-stranded telomeric DNA, TPP1
and POT1 proteins associate with the G-tail. TIN2 protein bridges
together both complexes (reviewed in [186]).
The protection of chromosome ends by telomeres is a multilayer
response in which distinct telomeric factors repress the activation
of different signaling and repair pathways. From biochemical data
based on the rejoining of a linear plasmid mediated by cellular
extracts or puriﬁed proteins, we  have proposed a double lock model
against end joining at telomeric ends in which the TRF2/RAP1 com-
plex inhibits C-NHEJ, whereas the DNA–PK complex blocks A-EJ
[187]. This model was further substantiated and reﬁned by data
obtained in cells [63,84,188]. Several reports have characterized
the ﬁrst lock level, demonstrating that different shelterin compo-
nents sustain different protective roles. TRF2 directly binds ATM
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AP1 to telomeres, thereby preventing telomeric fusions by C-
HEJ [193,194]. Biochemical studies in our lab have demonstrated
hat TRF2/RAP1 prevents proper Ku binding and DNA-PK activa-
ion at telomeric ends [187]. Thus, removal of TRF2 from telomeres
rovokes end-to-end chromosome fusions [195,196], which are
ainly dependent on Lig4 activity [188,195,197,198]. Moreover,
hese C-NHEJ dependent end-fusions are completely abrogated
n an ATM deﬁcient background [190] and require the C-NHEJ
acilitator 53BP1 [84]. ATM activation ensures 53BP1 recruitment
nd phosphorylation together with its association with RIF1 and
TIP, both to promote long range end-joining [199] and to prevent
esection at DNA ends [116,120,154,200].
In contrast to TRF2, it has been shown that TPP1-POT1 prevents
TR activation at telomeres since removal of TPP1-POT1 complex
ctivates ATR signaling, independently of the status of the TRF2
rotein [84,190–192]. In a murine 53BP1-null background, over-
xpression of a dominant negative form of TPP1, which globally
estabilizes the shelterin [192,201], induces telomeric fusions that
re completely abrogated in ATR depleted cells and independent of
ig4, thus relying on A-EJ; moreover, further depletion of TRF2 in
his model considerably increases the number of telomeric fusions
84]. Accordingly, total depletion of the shelterin complex in Lig4-/−
EFs yielded signiﬁcant telomere fusions by A-EJ [63]. Together
hese ﬁndings show that TRF2 and TPP1/POT1 proteins cooperate
o fully inhibit A-EJ at telomeric sequences.
Concerning the second lock at telomeres, several reports
upport a role for DNA-PK as a protection factor against A-
J. Spontaneous chromosome-end fusions are promoted by a
eﬁciency in either Ku [188,202–207] or DNA–PKcs [208,209],
hile at least in the absence of Ku, the core shelterin complex
ppears broadly normal [197]. Furthermore, depletion of Ku in
PP1/POT1 depleted cells or in shelterin-free telomeres provokes
 dramatic increase of A-EJ dependent chromosome-end fusions
63,84].
What are the factors involved in A-EJ acting on dysfunctional
elomeres? Consistent with the admitted players in A-EJ, inhibition
nd/or inactivation of PARP1 or Lig3 proteins signiﬁcantly reduced
he fusions of shelterin-free telomeres [63]. In addition to the ATR
ctivation [84,190] which may  act at an early step, a nucleolytic pro-
ess is required. Indeed, end-to-end fusions induced by TPP1/POT1
epletion are reduced to a background level in the absence of the
tIP protein [84]. 53BP1 functions as a brake on resection since
3BP1 depletion in cells with shelterin-free telomeres provokes an
mportant lengthening of the 3′ overhang, which is dependent on
LM, EXO1 and CtIP proteins [63]. Taken together these results sug-
est that shelterin components are required to block nucleolytic
egradation of telomeres and in the absence of shelterin, 53BP1
urther inhibits this degradation. A major role for Ku in protection
f telomeres from exonucleolytic attack in yeast and plants has
een described [210–214]. Notably, Ku complex appears to elicit
nly a moderate protection against end resection at deprotected
elomeres compared to the major effect of 53BP1 [63]. However,
revention of A-EJ by 53BP1 concerns telomeres already engaged
n damage signaling contrarily to Ku constitutively present at all
elomeres and which does not rely on damage signaling to coun-
eract A-EJ.
Aside  from A-EJ function at chromosome ends following arti-
cial induction of telomeric dysfunction, what is its impact on
aturally eroded telomeres? The maintenance of the telomeric
equence is ensured by the telomerase, a specialized ribonucle-
protein complex that counteracts the natural telomere attrition
ccurring at each cell division. In the absence of telomerase,
ammalian telomeres shorten from 50 to 100 bp per cell division
215]. When reaching a critical size, telomeres no longer protect
hromosome ends from the DNA Damage Response and are recog-
ized as DNA breaks. Eroded telomeres participate in end-to-end 17 (2014) 81–97
chromosome fusions and induce cell cycle arrest, senescence or
apoptosis [216].
In  2002, Espejel and co-workers have shown that chromo-
some end fusions in late generation telomerase-null mice, bearing
critically shortened telomeres, are dependent on Ku80 and DNA-
PKcs proteins [217]. However, experiments from DePinho’s lab
show that end-to-end chromosome fusions with critically short-
ened telomeres occur in the absence of Lig4 and DNA PKcs proteins
and could involve A-EJ [218], in line with the report of Ku- and
Lig4-independent telomere fusions on telomere attrition in ﬁssion
yeast and in plants [214,219,220]. Molecular characterization of
junction sequences of critically shortened human fused telomeres,
present regions of microhomologies as well as extensive telomere
deletions, both features reminiscent of A-EJ [221]. Finally, Rai and
co-workers demonstrated that naturally eroded telomeres were
prone to fuse despite the absence of the critical 53BP1 factor for
C-NHEJ, indicating that A-EJ operated [84]. Taken together these
data argue for a contribution of A-EJ to the processing of naturally
eroded telomeres.
5.3.  Contribution of A-EJ to chromosomal rearrangements and
cancer
Genomic  instability is a prominent hallmark of cancer that can
determine the acquisition of multiple additional cancer capabilities
[222]. Among various forms of genomic instability, chromosomal
instability has been incriminated as a causative factor in cancer
development for a century [223]. This view is fully supported by
the discovery of the Philadelphia chromosome, that is the recurrent
t(9;22) translocation associated with chronic myeloid leukemia
[224]. Although mutations affecting the sequence of genes are
more frequent than chromosomal rearrangements, translocation
are considered to drive 20–40% of cancers [225,226]. Transloca-
tions are a subtype of chromosomal aberrations in which parts
of two  different non-homologous chromosomes are fused. Recur-
rent translocations are commonly associated with haematopoietic
malignancies [173,227,228], although increasing amount of data
conﬁrms their implication in solid tumors as well [225]. In most
cancer cells, chromosomal aberrations are multiple and complex,
making it sometimes difﬁcult to ascertain whether a particular
rearrangement is a passenger mutation or an oncogenic driver. The
ﬁne analysis of chromosomal rearrangements has greatly beneﬁted
from recently developed powerful tools allowing genome-wide
translocation mapping and large-scale analysis of spatial nuclear
organization [229].
The  respective contribution of C-NHEJ and A-EJ in the origin of
translocations has been the subject of intense research in different
contexts and this issue is still being debated.
5.3.1. End-joining processes in chromosomal rearrangements
C-NHEJ may  account for translocation events in some speciﬁc
situations such as during the recovery from early apoptotic DNA
fragmentation [230–232], or in the pathogenesis of acute leukemias
secondary to cancer treatments based on Topoisomerase-II (TopoII)
inhibitors that frequently feature translocations involving the
mixed-lineage leukemia (MLL) gene [233,234]. The role of C-NHEJ
in chromosomal rearrangements has been more clearly established
in the special case of one-ended DSB repair following replication
fork collapse [235–238], but a recent study also suggests a sig-
niﬁcant role for A-EJ in the repair of one-ended DSBs following
hydroxyurea replication fork arrest [83].
Apart from these particular situations, most studies suggest
both a suppressive role for C-NHEJ core components and a promi-
nent role for A-EJ in mediating translocations. Indeed, spontaneous
chromosomal rearrangements including translocations are more
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broblasts or ES cells [239–242]. This effect is exacerbated upon
SB induction by ionizing irradiation [240]. The use of reporter
ystems in mouse ES cells conﬁrm and extend this observation.
epletion of Ku70 [81,243,244], XRCC4 [94,243] or Lig4 [94,243],
r DNA-PKcs inhibition [245] strongly increases translocation
requency without signiﬁcantly affecting the pattern of MH
ength at the breakpoint junctions when tested [81,94,243,246].
n C-NHEJ deﬁcient mice, cancer susceptibility is only slightly
nhanced, unless genomic gatekeepers like p53 are also deleted.
nterestingly, nearly all C-NHEJ/p53 double deﬁcient mice die from
ro-B lymphomas mostly associated with recurrent translocations
nvolving the immunoglobulin heavy chain locus (IgH) and c-myc
227]. High incidence of pro-B lymphomas has been described
n mice deﬁcient for both p53 and Ku80 [239,247], Ku70 [248],
NA-PKcs [249–251], Lig4 [252], XRCC4 [253], and Artemis,
lthough with different chromosomal rearrangements in the latter
ase [254]. Cer-XLF/p53 double deﬁcient mice do not exhibit high
ncidence of pro-B lymphomas [159], likely reﬂecting functional
edundancy with other factors such as ATM, H2AX and 53BP1
uring V(D)J recombination [255–257].
Recurrent translocations associated with pro-B lymphomas in
-NHEJ/p53 double deﬁcient mice likely result from aberrant repair
f RAG-induced DSBs. The additional deletion of RAG suppresses
he pro-B lymphoma high incidence in DNA-PKcs/p53 [258,259]),
u80/p53 [248] or XRCC4/p53 double-deﬁcient mice [260]. When
nalyzed, translocation breakpoint junctions revealed MH usage
ith no direct joints [248,260], further supporting the propensity
f A-EJ for catalyzing illegitimate end-joining events.
In  the absence of functional C-NHEJ, the A-EJ pathway is
lso implicated in chromosomal rearrangements following AID-
nduced DSBs during CSR. Although quite robust in replacing
-NHEJ during CSR (see above, section 5-1), A-EJ does not appear
ully adequate since B cells show frequent DSBs and translocations
152,156]. The conditional deletion of XRCC4 in mature B-cells of
53-null mice leads to peripheral B-cell lymphomas that mostly
ely on translocations between IgH and c-myc associated with MH
t the junction [261]. This observation further conﬁrms the crit-
cal role of C-NHEJ in suppressing A-EJ mediated translocations
uring CSR. A role for AID-induced DSBs in IgH/c-myc transloca-
ions was subsequently established [262]. Complex translocations
n pro-B lymphomas from RAG-induced DSBs in p53/C-NHEJ dou-
le deﬁcient mice routinely harbor c-myc and IgH ampliﬁcations
248,260]. In contrast, translocations found in peripheral B-cell
ymphomas originate from reciprocal rearrangements without c-
yc  ampliﬁcation, reminiscent of translocation events in Burkitt’s
ymphoma which also feature MH at the junction [263]. Further-
ore, the evidence of AID-induced DSBs both in IgH and c-myc
264] establishes the important role of AID in promoting IgH/c-myc
ranslocations even in C-NHEJ proﬁcient contexts [173,264].
Recently developed techniques for genome-wide translocation
equencing or analysis of chromatin spatial conformation indi-
ate that both the frequency of DSBs at off-target locations by AID
or RAG in immature B-cells) and the spatial proximity between
roken chromosomal regions contribute to the high frequency of
gH/c-myc translocations in B-cells during the CSR (or the V(D)J
ecombination) [265–268]. What are the respective roles of A-EJ
nd C-NHEJ in catalyzing IgH/c-myc translocations? Although the
ontribution of A-EJ is clear in the absence of functional C-NHEJ,
he choice between the two pathways remains unclear in wild-
ype B-cells. Nearly all translocation breakpoints use 1–7 bp of MH
hen DSBs are induced by I-SceI both in c-myc and IgH, similar to
hat is found in C-NHEJ-deﬁcient B-cells [264]. In contrast, when
SBs are produced by I-SceI and AID in c-myc and IgH, respectively,
bout half of the junctions are direct and the overall MH usage is
nder 1 bp, reminiscent of the junctions observed during normal
SR between switch regions [152]. This result is consistent with 17 (2014) 81–97 89
a  major role for C-NHEJ in the formation of translocations during
CSR. This may  also reﬂect a form of coupling between AID-mediated
cleavage and the C-NHEJ machinery, although less stringent than
between RAG-induced DSBs and C-NHEJ. This notion is further sup-
ported by the different ability of S compared to other S regions to
participate in translocations [269]. Alternatively, the mechanism
of production of DSBs, by affecting the nature of DNA ends, may
inﬂuence the way  they are processed by the A-EJ machinery, thus
giving rise to more or less MH  at the junction.
Outside the context of CSR, by using translocation reporter sys-
tems in mouse, the unmodiﬁed pattern of MH usage whatever Ku
or Lig4 status, strongly argues in favor of a prominent role for A-EJ
in catalyzing translocations [81,94,243]. Importantly, this method
also provides compelling evidence relative to the mechanism of
A-EJ. It has established the role of CtIP in the early resection step
[81], as well as the major role of Lig3 in translocation formation,
including its nearly full dominance over Lig1 and an apparent dis-
pensability for XRCC1 [94], consistent with other studies [32,95].
In addition the role of PARP1 in promoting translocations was also
evidenced, both in murine and human cells, following nuclease-,
IR- or etoposide-induced DSBs [245], or in the context of CSR
[62].
5.3.2. End-joining processes in cancer
So far in human tumors, the estimated contribution of A-EJ to
translocation formation mainly rely on indirect evidence based
on MH at breakpoint junctions commonly observed in haemato-
logical malignancies [227,228] and also in various solid cancers
[270–272]. In support of a role of A-EJ in carcinogenesis, several
studies suggested the notion that the balance between C-NHEJ
and A-EJ might be shifted toward the latter in tumor cells, thus
accounting for genetic instability. Recently, using an integrated A-
EJ reporter system, tumor cells where shown to use signiﬁcantly
more A-EJ than non tumor immortalized cells [83], consistent
with several earlier observations. For instance, BCR-ABL-positive
chronic myeloid leukemia (CML) cells overproduce reactive oxygen
species (ROS) and repair ROS-induced DSBs through error-prone
pathways including end-joining with large deletions [273]. This
observation was extended and supported by showing reduced
protein expression level of Lig4 and Artemis in CML  cell lines
together with an up-regulation of Lig3 and WRN  proteins, both
being involved in a substantially active end-joining subpath-
way which uses MH [274]. Similarly, FMS-like tyrosine kinase
3/internal tandem duplication (FLT3/ITD)-positive acute myeloid
leukemia cells also accumulate more ROS and subsequent DSBs
[274]. Moreover, compared to control cells expressing wild-type
FLT3, FLT3/ITD-positive cells resort partly to a low-ﬁdelity MH-
based end-joining process for repairing DSBs, in line with both an
increased Lig3 and a decreased Ku expression levels [275]. Both
deletion extent and MH  usage were reduced upon treatment with
an FLT3 kinase inhibitor or by down-regulating Lig3 expression
level, suggesting an increased contribution of A-EJ in DSB repair in
FLT3/ITD cells [275]. Cells from FLT3/ITD knock-in mice essentially
exhibited similar differences in end-joining characteristics and pro-
tein expression pattern, compared to wild-type cells [275]. More
recently, in murine FLT3/ITD-positive pro-B cells, a PARP1 over-
expression was  also described concomitantly with a decrease of
Ku expression which resulted in a DSB repair defect and impaired
V(D)J recombination that could be alleviated upon inhibition of
FLT3 [276].
Together, these results indicate that, through an hitherto unclear
mechanism, oncogenic tyrosine kinases may be critical in cer-
tain circumstances for regulating the balance between C-NHEJ and
A-EJ in cancer cells, thus promoting genomic instability. In line
with this notion, tumor progression and agressiveness were also
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ell carcinomas [277], as well as in breast and bladder cancers
278]. Interestingly, in both studies, early stages of cancer rather
ppear to correlate with an increased Ku activity, thus suggest-
ng a two-phase dynamics in cancer progression with an early
-NHEJ overactivity and a late shift toward A-EJ. Independently,
SB repair activity was further analyzed in several bladder cancers
ith an in vitro end-joining assay that demonstrated in high-grade
umors a preference for using a C-NHEJ-independent, error-prone
nd MH-mediated DSB repair pathway [279]. Strikingly, a more
ecent proteomic analysis on several B-cell samples from patients
ith Waldenström’s macroglobulineamia revealed a strong down-
egulation of Ku70 which pathophysiological meaning remains to
e evaluated [280].
Altogether  these data provide a rationale for designing novel
nticancer chemotherapy targeting A-EJ. Recent papers described
 promising strategy combining both existing PARP1 inhibitors and
ewly developped Lig3 inhibitors to preferentially kill hormone-
esistant breast cancer cells [281] or CML  cells resistant to
CR-ABL-directed tyrosine kinases [282] that exhibit elevated
ARP1 and Lig3 expression levels. C-NHEJ and A-EJ components
ight then be considered as novel biomarkers to identify can-
idate tumors potentially responding to therapy targeting either
-NHEJ (mainly through inhibition of DNA-PKcs [12] or Lig4 [283])
r A-EJ. Alternatively, adjuvant therapy based on PARP1 inhibitors
ay help contain chromosomal rearrangements mediated by A-EJ
uring conventional cancer treatment.
Overall, mounting evidence support a key role for A-EJ in
hromosomal instability including translocation formation, which
ay  represent the most relevant biological impact of this path-
ay. However, although MH is frequently found at translocation
reakpoint junctions in haematological malignancies and in solid
ancers, evaluating conﬁdently the contribution of A-EJ in carcino-
enesis will require a sharper landscape of the mechanism and
peciﬁc components of this pathway.
. Concluding remarks
.1.  A-EJ: a single pathway or multiple pathways?
During the past decade, considerable effort has been made to
nravel the physiological functions of A-EJ and to elucidate its
nderlying molecular mechanism. Nonetheless, despite the obvi-
us dependence on Lig3 and/or Lig1 and a trend toward MH  usage
elying on resection promoted by MRN  and CtIP, no speciﬁc genetic
r mechanistic attributes have been conclusively established so
ar (see Fig. 1). Moreover, regarding the reliance on MH,  two  dif-
erent A-EJ pathways have been proposed based on experiments
n CSR in the absence of XRCC4/Lig4, Ku70 or both [149,163].
oss of Lig4 (or XRCC4) results in CSR junctions harboring almost
xclusively MH,  while 10–15% of junctions retain direct joints
n Ku70 or Ku70/Lig4 deﬁcient B cells. From these ﬁndings A-EJ
as proposed to encompass at least two pathways: (i) a Ku-
ependent/Lig4-independent pathway relying solely on MHs, (ii)
 Ku-independent/Lig4-independent pathway still capable of car-
ying out some direct end joining [149,163]. However, it is also
onceivable that the different CSR outcomes result from the neces-
ity for a single A-EJ complex to overcome the binding of Ku at
NA ends when present, potentially through an MRN-dependent
nternal nucleolytic attack as reported in yeast [284]. Therefore,
omewhat counterintuitively, under C-NHEJ deﬁciency conditions
ut in the presence of Ku (absence of XRCC4/Lig4), joining would
equire removal of the abortive C-NHEJ complex by resection, lead-
ng to an increased use of MHs, while in the absence of Ku, DNA ends
ould be more accessible to direct joining.
From the aforementioned studies and on the basis of genetic
nalysis of translocation mechanism in mouse cells [94] together 17 (2014) 81–97
with  in vitro end joining assays investigating the relative use of MHs
by Lig3 and Lig1 [91], it was further speculated that Lig3 and Lig1
might speciﬁcally operate in the Ku-dependent/Lig4-independent
and  the Ku-independent/Lig4-independent A-EJ pathways, respec-
tively. However, both in mouse and chicken cells and with different
sources of DSBs, Lig3 appears to largely dominate Lig1 which serves
at best as a backup ligase when both Lig4 and Lig3 are absent
[94,102].
Consequently, since many other interpretations are also pos-
sible, further experiments are needed to unequivocally establish
whether A-EJ rely on a single pathway or on various (sub)pathways
depending on the context. Alternatively, a simpler possibility still
exists that A-EJ would not be a genuine repair pathway at all.
6.2.  A-EJ: the “no pathway” option
Several lines of evidence argue against A-EJ being a true repair
pathway.
First, as said before, the putative A-EJ mechanism is still ill-
deﬁned, although resembling a combination of components from
the HR and/or SSA pathways as well as from the excision repair
machineries surch as BER or NER (Fig. 1). Moreover, A-EJ seems
highly versatile with respect to the subsets of proteins potentially
involved, the nature of the breaks used as substrates and the variety
of sequence, chromatin and cellular contexts in which alternative
end-joining can operate. The A-EJ ﬂexibility is also reﬂected by the
repair outcome (itself inﬂuenced by the previously mentioned ele-
ments) ranging from direct and accurate rejoining to deletional
repair events, with or without MHs  or insertions at the junc-
tion, and ultimately to illegitimate rejoining reactions resulting in
translocations and other chromosomal rearrangements. Although
not strictly dependent on MH,  the bias toward MH may  provide
some stability between DNA ends, thus potentially compensating a
lack of protein factors speciﬁcally devoted to carrying out a synap-
sis during A-EJ. In fact the absence of stable synapsis appears to
be the weak point of A-EJ and may  explain the low ﬁdelity of this
process.
Second, no relevant physiological function has been uncovered
for A-EJ which seems not to have carved out a place to operate
as a ﬁrst choice pathway. Much to the contrary, A-EJ is highly
error-prone both at the sequence level and in legitimately rejoin-
ing DNA ends, leading to frequent DNA loss at the junctions and to
chromosomal rearrangements, respectively. As a result, the only
appreciable cellular impact of A-EJ rather relies on pathological
events, as discussed in this review. CSR is no exception, and even
if AID-induced DSBs in S regions would appear fairly amenable to
repair by A-EJ, C-NHEJ is necessary for efﬁcient CSR and cannot be
adequately replaced by A-EJ. Recently, variations between relative
C-NHEJ and A-EJ activities assessed in vitro with cell free extracts
prepared from mouse embryos at different stages of development,
suggested a role for A-EJ during embryogenesis [285]. However
in vivo experiments are required to conﬁrm and conﬁdently inter-
pret these ﬁndings.
Finally,  in non pathological situations and in wild-type genetic
contexts, A-EJ activity is limited; C-NHEJ largely dominates other
pathways at two-ended DSBs, while HR speciﬁcally deals with one-
ended DSBs arising in S phase and with some two-ended complex
DSBs lying in heterochromatin in S/G2.
Consequently, cells seem to have evolved to stave off as much
as possible any attempt to deal inadequately with free DNA ends,
particularly by setting up safe synapses soon after DSB appearance,
or even before, during physiological processes such as V(D)J recom-
bination, CSR and meiosis (Fig. 3). The core components of C-NHEJ
provide the basis for this synapsis which is further strengthened
by partially overlapping or complementary factors like chromatin
modiﬁcations, MRN  or 53BP1 bridging activities, as well as more
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Fig. 3. Interplay between DSB repair pathways—Inﬂuence of the origin and nature of breaks. (a) Physiological four-ended DSBs are formed in G1 and are tightly shepherded
to C-NHEJ, particularly RAG-dependent breaks arising during V(D)J and to a lesser extent AID-dependent breaks during CSR. C-NHEJ fully dominates A-EJ although A-EJ can
partly  rescue CSR when C-NHEJ is ablated. Note that in case of C-NHEJ deﬁciency, persistent CSR-mediated DSBs can also be repaired by HR in G2.  (b) Meiotic DSBs are
channeled to HR which is further supported by the lack of Ku and 53BP1 protein expression at the time point of meiotic recombination. (c) Accidental two-ended DSBs are
essentially repaired by C-NHEJ, especially in the case of TopoII cleavable complexes (TopoIIcc). In S and G2, HR may  also contribute to the repair of a subset of DSBs. In any case,
































[17]  E. Rampakakis, D. Di Paola, M.  Zannis-Hadjopoulos, Ku is involved in cell
growth, DNA replication and G1-S transition, J. Cell Sci. 121 (2008) 590–600.3BP1/RIF1, is performed by HR-mediated pathways. PARP1 also participates in C-N
epair  events. (e) Telomeres are protected from unwanted fusions through a multip
-NHEJ  and A-EJ, while DNA-PK also silences A-EJ. For each situation, the resulting pr
reen  = no repair.
peciﬁcally RAG1/2 during the V(D)J recombination and TopoII
tself when failing or when blocked as a cleavable complex. Telom-
ric ends are also protected from end joining by A-EJ through a
ouble lock involving the shelterin complex and DNA-PK.
As  a result, A-EJ may  be viewed as an opportunistic catch-all
rocess using any available activity to reseal escaped DNA ends
hen possible; this bricolage operates at the expense of genetic
tability. However, in line with its early suggested backup function
28], A-EJ could be of some utility as a last-ditch attempt to join
NA ends when C-NHEJ and HR pathways are overwhelmed with
oo many DSBs. Conceivably, another long-term beneﬁcial aspect of
-EJ would concern genome plasticity and evolution. In this respect
eletions represent the most frequent mutational events and might
otentially be contributed by A-EJ [286]. Interestingly, intron loss
uring evolution in metazoans was recently reported to rely on
H-mediated end joining [287].
Whether or not it is a genuine DSB repair pathway, A-EJ is
merging as an important cellular process in several pathological
ituations and its full characterization remains a major research
rea for the coming years.
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